UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032513
Receipt number R000036988
Scientific Title Prognostic relevance of instantaneous wave-Free Ratio in patients with ischemic heart disease undergoing directional coronary atherectomy followed by a paclitaxel-coated balloon angioplasty
Date of disclosure of the study information 2018/05/09
Last modified on 2023/05/12 17:12:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prognostic relevance of instantaneous wave-Free Ratio in patients with ischemic heart disease undergoing directional coronary atherectomy followed by a paclitaxel-coated balloon angioplasty

Acronym

Prognostic utility of instantaneous wave-Free Ratio in paclitaxel-coated balloon after directional coronary atherectomy

Scientific Title

Prognostic relevance of instantaneous wave-Free Ratio in patients with ischemic heart disease undergoing directional coronary atherectomy followed by a paclitaxel-coated balloon angioplasty

Scientific Title:Acronym

Prognostic utility of instantaneous wave-Free Ratio in paclitaxel-coated balloon after directional coronary atherectomy

Region

Japan


Condition

Condition

ischemic heart disease

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the association between intravascular ultrasound (IVUS) and instanteneous Wave-Free ratio (iFR) parameters and the mid to long term clinical events in patients with ischemic heart disease undergoing directional coronary atherectomy followed by a drug-coated balloon angioplasty

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Protcol 1, acute phase complications (intravascular ultrasound detected deep cut (either resection of media or adventitia) and/or coronary perforation) and 3 month major adverse cardiac event (MACE) including all-cause death, non-fatal myocardial infarction, clinically driven target lesion revascularization (TLR) defined as any repeat percutaneous coronary intervention or aortocoronary bypass surgery and a diameter stenosis >50% associated with symptoms or objective signs of ischemia (stress electrocardiogram, myocardial perfusion imaging, fractional flow reserve and instantaneous wave-free ratio)
Protcol 2, acute phase complications and 1 year MACE
Protcol 3, acute phase complications and long term MACE (>1 year)

Key secondary outcomes

bailout stenting for flow-limiting dissection, late lumen loss, binary restenosis, follow-up iFR, follow-up focal delta-iFR (treated lesion), procedure time, clinically driven target vessel revascularization


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

instantaneous wave-Free Ratio evaluation in patients undergoing directional coronary atherectomy followed by a drug-coated balloon angioplasty

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

directional coronary atherectomy (DCA) target lesion was selected as following criteria;

native coronary artery lesion located in non-ostial left main trunk or right coronary artery, ostium of the left anterior descending or left circumflex artery, or a major bifurcation located at the proximal left anterior descending or left circumflex

symptomatic angina or objective signs of ischemia (stress electrocardiogram, myocardial perfusion imaging, fractional flow reserve, or instantaneous wave-free ratio)

lesion stenosis 50%< and <100%, and 15 mm or less in length by visual estimation

de novo lesion or plain old balloon angioplasty restenotic lesion

vessel suitable for transfemoral approach (DCA device size 7 French or more)

age between 20 and 85-years-old

signed written informed consent


The revascularization (with or without a stent) of distal non-target major vessel lesion in proximity to the target lesion was permitted during the index procedure to achieve iFR-based endpoint (iFR>0.89).

Bailout stenting for target lesion was performed only in cases of a suboptimal result, defined as flow-limiting dissection and/or a persistent residual stenosis refractory to optimal directional coronary atherectomy and balloon dilation. It was reported as "Bailout stenting" separately from the acute phase complications (described below).
(Acute complications were defined as intravascular ultrasound detected deep cut (either resection of media or adventitia) and/or coronary perforation in the target lesion, and adequately treated by watchful waiting, perfusion PTCA, stents, covered-stents, or emergency CABG.)

Key exclusion criteria

culprit lesion for acute myocardial infarction within 2 weeks

Aorto-ostial lesion

presence of thrombus at the lesion

stent or directional coronary atherectomy restenotic lesion

angulated lesion >60 degree

diffuse disease

significant tortuosity

severe peripheral vascular disease

markedly calcified lesion by angiography and/or superficial calcium >180 degree detected by IVUS

attenuated plaque (>180 degree) detected by IVUS

contraindication or intolerance to paclitaxel, aspirin, thienopyridines, or contrast media, and concomitant significant medical condition

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Arata
Middle name
Last name Hagikura

Organization

Tsukazaki Hospital

Division name

Department of Cardiology

Zip code

6711227

Address

68-1 Waku, Aboshi-ku, Himeji, Hyogo

TEL

+81-79-272-8555

Email

hagikuraarata@hotmail.co.jp


Public contact

Name of contact person

1st name Arata
Middle name
Last name Hagikura

Organization

Tsukazaki Hospital

Division name

Department of Cardiology

Zip code

6711227

Address

68-1 Waku, Aboshi-ku, Himeji, Hyogo

TEL

+81-79-272-8555

Homepage URL


Email

hagikuraarata@hotmail.co.jp


Sponsor or person

Institute

Department of Cardiology, Tsukazaki Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)

Philips (intravascular ultrasound catheter, This study is NOT receiving any funding.)


IRB Contact (For public release)

Organization

Tsukazaki Hospital

Address

68-1 Waku, Aboshi-ku, Himeji, Hyogo

Tel

+81-79-272-8555

Email

y-fu@tsukazaki-hp.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 05 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 05 Month 08 Day

Date of IRB

2018 Year 05 Month 01 Day

Anticipated trial start date

2018 Year 05 Month 09 Day

Last follow-up date

2025 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 05 Month 08 Day

Last modified on

2023 Year 05 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036988


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name